Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted
Unite.AI ·
Summary
Harbour BioMed announced on November 18, 2026 that China’s National Medical Products Administration had accepted the investigational new drug (IND) application for LET003, its first drug candidate developed using the Hu-mAtrIx AI platform. The monoclonal antibody is intended to t
- Source
- Unite.AI
- Published (IST)
Original reporting belongs to Unite.AI. DEEKOYA links the headline and a short excerpt only; we do not republish the full article.
Explore more: Today in AI · Research papers · AI tools · Learn AI
Related stories
TechCrunch AI
Microsoft CEO Satya Nadella explains why he asked 60K employees to quit
Microsoft CEO Satya Nadella explained why he offered buyouts to 60,000 of his employees in October, essentially urging…
TechCrunch AIBusiness
Unite.AI
AWS Brings Full-Weight Training To Serverless SageMaker Customization
Amazon Web Services announced on November 18, 2026 full fine-tuning (FFT) support for SageMaker AI Serverless Model…
Unite.AIModels
NYT Technology
How Nvidia Chips Ended Up Within Reach of China’s Military
Alibaba, the Chinese internet giant behind the company at the center of the Nvidia spy saga, has used its A.I.…
NYT TechnologyHardware
Unite.AI
Perplexity Brings Voice-Controlled AI Teammates to Mobile
Perplexity on November 18, 2026 added voice mode for its AI teammates on iOS and Android, giving Max subscribers a way…
Unite.AIModels
SiliconANGLE AI
Google Cloud brings AI agents to the supercomputing bottleneck
High-performance computing, or HPC, is merging with artificial intelligence faster than many research teams can adapt.…
SiliconANGLE AIHardware
SiliconANGLE
HPC meets AI agents as Google Cloud targets time to discovery
SiliconANGLEAI
Who reported “Harbour BioMed’s AI-Enabled Obesity Antibody LET003 Has IND Accepted”?
Unite.AI, on 19 Nov 2026. The full article is at the source link on this page.
Comments
No comments yet. Share your own experience below.
Visitor posts are moderated before they appear and are the opinion of their authors, not DEEKOYA AI. Names are not verified. See our privacy policy.